The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: Therapeutic applications

Blood

Volumn 101, Issue 6, 2003, Pages 2377-2380

  Mitsiades, Nicholas ^b   Mitsiades, Constantine S ^b   Richardson, Paul G ^b   Poulaki, Vassiliki ^b   Tai, Yu Tzu ^b   Chauhan, Dharminder ^b   Fanourakis, Galinos ^b   Gu, Xuesong ^b   Bailey, Charles ^b   Joseph, Marie ^b   Libermann, Towia A ^b   Schlossman, Robert ^b   Munshi, Nikhil C ^b   Hideshima, Teru ^b   Anderson, Kenneth C ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BORTEZOMIB; DOXORUBICIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MELPHALAN; PROTEASOME INHIBITOR;

ADULT; APOPTOSIS; ARTICLE; CANCER RECURRENCE; CASE REPORT; CONTROLLED STUDY; DISEASE EXACERBATION; DNA DAMAGE; DOWN REGULATION; DRUG POTENTIATION; DRUG SENSITIZATION; FATIGUE; GENE EXPRESSION REGULATION; GENOTOXICITY; HUMAN; HUMAN CELL; MALE; MULTIPLE MYELOMA; MYELOMA CELL; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; SIDE EFFECT;

EID: 0037443551     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2002-06-1768     Document Type: Article

References (25)

1. Hideshima T, Chauhan D, Schlossman R, Richardson P, Anderson KC. The role of tumor necrosis factor alpha in the pathophysiology of human multiple myeloma: therapeutic applications. Oncogene. 2001;20:4519-4527.
2. HideshimaT,Chauhan D, Richardson P, et al. NF-kappa B as a therapeutic target in multiple myeloma. J Biol Chem. 2002;277:16639-16647.
3. Mitsiades N, Mitsiades CS, Poulaki V, et al. Molecular sequelae of proteasome inhibition in human multiple myeloma cells. Proc Natl Acad Sci U S A. 2002;99:14374-14379.
4. Hideshima T, Mitsiades C, Akiyama M, et al. Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341. Blood. 2003;101:1530-1534.
5. Hideshima T, Richardson P, Chauhan D, et al. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res. 2001;61:3071-3076.
6. LeBlanc R, Catley LP, Hideshima T, et al. Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model. Cancer Res. 2002;62:4996-5000.
7. Richardson PG, Barlogie B, Berenson J, et al. Phase II study of the proteasome inhibitor PS-341 in multiple myeloma (MM) patients (pts) with relapsed/refractory disease [abstract]. Am Soc Clin Oncol Annu Meeting Proc. 2002:11a.
8. Mitsiades CS, Treon SP, Mitsiades N, et al. TRAIL/Apo2L ligand selectively induces apoptosis and overcomes drug resistance in multiple myeloma: therapeutic applications. Blood. 2001;98:795-804.
9. Zhang H, Shi X, Zhang Q-J, et al. Nocodazole-induced p53-dependent c-Jun N-terminal kinase activation reduces apoptosis in human colon carcinoma HCT116 cells. J Biol. Chem. 2002;277:43648-43658.
10. Mitsiades CS, Mitsiades N, Poufaki V, Akyiama M, Treon SP, Anderson KC. High-throughput global proteomic analysis of the signaling state of human multiple myeloma cells [abstract]. Blood. 2001;98:733a.
11. Mitsiades N, Poulaki V, Kotoula V, Leone A, Tsokos M. Fas ligand is present in tumors of the Ewing's sarcoma family and is cleaved into a soluble form by a metalloproteinase. Am J Pathol. 1998; 153:1947-1956.
12. Wang CY, Mayo MW, Baldwin AS Jr. TNF-α and cancer therapy-induced apoptosis: potentiation by inhibition of NF-kappaB. Science. 1996;274:784-787.
13. Mitsiades N, Mitsiades CS, Poulaki V, et al. Biologic sequelae of NF-κB blockade in multiple myeloma: therapeutic applications. Blood. 2002;99:4079-4086.
14. Damiano JS, Dalton WS. Integrin-mediated drug resistance in multiple myeloma. Leuk Lymphoma, 2000;38:71-81.
15. Damiano JS, Cress AE, Hazlehurst LA, Shtil AA, Dalton WS. Cell adhesion mediated drug resistance (CAM-DR): role of integrins and resistance to apoptosis in human myeloma cell lines. Blood. 1999;93:1658-1667.
16. Hazlehurst LA, Dalton WS. Mechanisms associated with cell adhesion mediated drug resistance (CAM-DR) in hematopoietic malignancies. Cancer Metastasis Rev. 2001;20:43-50.
17. Hazlehurst LA, Damiano JS, Buyuksal I, Pledger WJ, Dalton WS. Adhesion to fibronectin via beta1 integrins regulates p27kip1 levels and contributes to cell adhesion mediated drug resistance (CAM-DR). Oncogene. 2000;19:4319-4327.
18. Shain KH, Landowski TH, Dalton WS. Adhesion-mediated intracellular redistribution of c-Fas-associated death domain-like IL-1-converting enzyme-like inhibitory protein-long confers resistance to CD95-induced apoptosis in hematopoietic cancer cell lines. J Immunol. 2002;168:2544-2553.
19. Hazlehurst LA, Valkov N, Wisner L, et al, Reduction in drug-induced DNA double-strand breaks associated with beta1 integrin-mediated adhesion correlates with drug resistance in U937 cells. Blood. 2001;98:1897-1903.
20. Garkavtsev IV, Kley N, Grigorian IA, Gudkov AV. The Bloom syndrome protein interacts and cooperates with p53 in regulation of transcription and cell growth control. Oncogene. 2001;20:8276-8280.
21. Rosenquist TA, Zharkov DO, Grollman AP. Cloning and characterization of a mammalian 8-oxoguanine DNA glycosylase. Proc Natl Acad Sci U S A. 1997;94:7429-7434.
22. Sixma TK. DNA mismatch repair: MutS structures bound to mismatches. Curr Opin Struct Biol, 2001;11:47-52.
23. Featherstone C, Jackson SP. DNA double-strand break repair. Curr Biol. 1999;9:R759-761.
24. Mitsiades N, Mitsiades CS, Poulaki V, et al. Apoptotic signaling induced by immunomodulatory thalldomide analogs (IMiDs) in human multiple myeloma cells: therapeutic implications. Blood. 2002;99:4525-4530.
25. Cusack JC Jr, Liu R, Houston M, et al. Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: implications for systemic nuclear factor-kappaB inhibition. Cancer Res. 2001;61:3535-3540.